v3.26.1
Cover - USD ($)
 12 Months Ended
Dec. 31, 2025
Mar. 31, 2026
Jun. 30, 2025
Cover [Abstract]      
Document Type 10-K    
Amendment Flag false    
Document Annual Report true    
Document Transition Report false    
Document Period End Date Dec. 31, 2025    
Document Fiscal Period Focus FY    
Document Fiscal Year Focus 2025    
Current Fiscal Year End Date --12-31    
Entity File Number 001-41615    
Entity Registrant Name Mangoceuticals, Inc.    
Entity Central Index Key 0001938046    
Entity Tax Identification Number 87-3841292    
Entity Incorporation, State or Country Code TX    
Entity Address, Address Line One 17130 Dallas Parkway    
Entity Address, Address Line Two Suite 240    
Entity Address, City or Town Dallas    
Entity Address, State or Province TX    
Entity Address, Postal Zip Code 75248    
City Area Code (214)    
Local Phone Number 242-9619    
Title of 12(b) Security Common Stock, $0.0001 Par Value Per Share    
Trading Symbol MGRX    
Security Exchange Name NASDAQ    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Non-accelerated Filer    
Entity Small Business true    
Entity Emerging Growth Company true    
Elected Not To Use the Extended Transition Period false    
Entity Shell Company false    
Entity Public Float     $ 14,725,437
Entity Common Stock, Shares Outstanding   16,967,420  
Documents Incorporated by Reference [Text Block] None    
ICFR Auditor Attestation Flag false    
Document Financial Statement Error Correction [Flag] false    
Entity Listing, Par Value Per Share $ 0.0001    
Auditor Firm ID 76    
Auditor Opinion [Text Block] We have audited the accompanying consolidated balance sheets of Mangoceuticals, Inc. and Subsidiaries (the “Company”) as of December 31, 2025 and 2024, and the related consolidated statements of operations, comprehensive loss, changes in stockholders’ equity (deficit), and cash flows for the years then ended, and the related notes to the consolidated financial statements (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2025, and 2024, and the results of its operations and its cash flows for the years then ended December 31, 2025, in conformity with accounting principles generally accepted in the United States of America.    
Auditor Name Turner, Stone & Company, L.L.P.    
Auditor Location Dallas, Texas